During a Community Case Forum event, Antoinette R. Tan, MD, MHS, discussed the DESTINY-Breast04 and DESTINY-Breast06 trials ...

The lone unrated drug was trastuzumab deruxtecan (Enhertu). Thirty-nine of the rated drugs (80%) were classed as having a high added benefit, and 9 (18%) were classified as having a low added benefit.

The past decade in oncology has been marked by the rise of immunotherapy, which leverages the immune system to attack tumors. For many solid tumors, immune checkpoint inhibitors have supplanted ...

All patients had prior chemotherapy, half the patients had endocrine therapies, 80% had prior trastuzumab, 70% had ado-trastuzumab emtansine (Kadcyla), and 25% had prior trastuzumab deruxtecan ...

To date, the only HER2-targeted therapy approved by the U.S. Food and Drug Administration (FDA) for NSCLC is trastuzumab deruxtecan ... diarrhea, or pneumonitis—toxicities that were observed ...

Daiichi Sankyo has submitted a supplemental New Drug Application (sNDA) to Japan’s Ministry of Health, Labour and Welfare (MHLW) for Enhertu (trastuzumab deruxtecan) for the treatment of adult ...

(UVA Health) Patients with metastatic HER2-positive breast cancer lived significantly longer without disease progression when they received trastuzumab deruxtecan (Enhertu) in combination with ...

Fatal adverse reactions occurred in 1% of patients, including one case each of pneumonitis, septic shock, colitis, and hepatitis. Study results will be presented at the 2025 American Association ...

For the most up-to-date information, consult Health Canada's NOC database. Enhertu (trastuzumab deruxtecan): Authorization with conditions Health Canada has issued a Notice of Compliance, under the ...

trastuzumab deruxtecan (Enhertu). One of the program chairs, Matthew G. Vander Heiden, MD, PhD, director of the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of ...

As for safety, immune-mediated adverse events among patients treated with penpulimab included pneumonitis, colitis, hepatitis, endocrinopathies, nephritis with renal dysfunction, and skin reactions.